The ABCP (atezolizumab plus platinum‐based chemotherapy and bevacizumab) arm in the IMpower150 study is the first and only reported example of a survival benefit for ICI‐based combination therapy in EGFR‐mutant NSCLC patients who failed to respond to prior treatment with TKIs, achieving an ORR of 72% and a median OS of 19.4 months.27 Here, EGFR is linked to non-small cell lung carcinoma.